Prime Therapeutics and Magellan Rx Management completed the acquisition of a minority stake in Capital Rx.

Prime Therapeutics and Magellan Rx Management, a pharmacy solutions organization, completed the acquisition of a minority stake in Capital Rx, a health care technology solutions provider. Financial terms were not dsiclosed. “It is imperative for our industry to modernize our technology for the benefit of clients and patients. We evaluated several other platforms and quickly recognized that JUDI represents a new industry standard. This move will enable us to accelerate our pace of innovation while enhancing our core capabilities and ensuring state-of-the-art security. Our ability to utilize JUDI in combination with Prime’s core strengths makes me more confident than ever that Prime will set a new standard for pharmacy solutions,” Mostafa Kamal, Prime President and CEO.